HIV in pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 2, 2005, Pages 117-121

  Moodley, Jack ^a   Wennberg, Jens L ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Nelson R Mandela School of Medicine ^*  (United States)

Author keywords

HIV; Mother to child transmission; Pregnancy; Prevention; Testing

Indexed keywords

ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; ASCORBIC ACID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RETINOL; RITONAVIR; SAQUINAVIR; VITAMIN B GROUP; ZIDOVUDINE;

BIRTH DEFECT; BREAST FEEDING; CESAREAN SECTION; CLINICAL TRIAL; DELIVERY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE MUTATION; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LACTIC ACIDEMIA; LONG TERM CARE; MORBIDITY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; VAGINAL DELIVERY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION;

EID: 15944370598     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000162178.38231.1d     Document Type: Review

References (37)

1. Krishnakumar A. AIDS: promising microbicides. Frontline 2004; 21(14), http://www.flonnet.com [Accessed 29 November 2004].
2. Buiterys M, Jamieson DJ, O'Sullivan MJ, et al. Mother-Infant Rapid Intervention at Delivery (MIRIAD) Study Group. Rapid HIV-1 testing during labour: a multicenter study. JAMA 2004; 292:219-223. This study shows that women who have not been tested antenatally can be successfully tested in labour to provide prophylactic treatment to mother and infant.
3. Forsyth BW, Barringer SR, Walls TA, et al. Rapid HIV testing of women in labour: too long a delay. J Acquir Immune Defic Syndr 2004; 35:151-154.
4. Urban M, Chersich M. Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care. S Afr Med J 2004; 94:362-366.
5. de Paoli MM, Manongi R, Klepp KI. Factors influencing acceptability of voluntary counselling and HIV-testing among pregnant women in Northern Tanzania. AIDS Care 2004; 16:411-425.
6. Breese P, Burman W, Shlay J, Guinn D. The effectiveness of a verbal opt-out system for human immunodeficiency virus screening during pregnancy. Obstet Gynecol 2004; 104:134-137.
7. Prasitwattanaseree S, Lallemant M, Costagliola D, et al. Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants. Antivir Ther 2004; 9:179-185.
8. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:430-436.
9. Shetty AK, Coovadia HM, Mirochnick MM, et al. HIVNET 023 Study Team. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003; 34:482-490.
10. Garcia-Bujalance S, Ruiz G, De Guevara CL, et al. Quantitation of human immunodeficiency virus type 1 RNA loads in cervicovaginal secretions in pregnant women and relationship between viral loads in the genital tract and blood. Eur J Clin Microbiol Infect Dis 2004; 23:111-115.
11. Fawzi W, Msamanga G, Antelman G, et al. Effect of prenatal vitamin supplementation on lower-genital levels of HIV type 1 and interleukin type 1 beta at 36 weeks of gestation. Clin Infect Dis 2004; 38:716-722.
12. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 2002; 288:189-198.
13. Cunningham CK, Chaix ML, Rekacewica C, et al. Development of resistance mutations in women on standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal HIV-1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181-188.
14. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
15. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240. Clinical evidence of nevirapine resistance in mothers who later required treatment for their own health, and had single-dose nevirapine for PMTCT.
16. Giuliano M, Palmisano L, Galluzzo CM, et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003; 17:1570-1572.
17. Panburana P, Sirinavin S, Phuapradit W, et al. Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1. Am J Obstet Gynecol 2004; 190:803-808.
18. Ferrero S, Bentivoglio G. Post-operative complications after caesarean section in HIV-infected women. Arch Gynecol Obstet 2003; 268:268-273.
19. Fiore S, Newell ML, Thorne C. European HIV in Obstetrics Group. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18:933-938.
20. Covington DL, Conner SD, Doi PA, et al. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004; 103:1181-1189. No abnormal birth defects have been found after nelfinavir exposure in utero.
21. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782-789. This study examines the presence of elevated levels of lactic acid (of unknown clinical significance) in exposed infants and encourages long-term follow-up.
22. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18:1013-1021.
23. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-2061.
24. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://www.AIDSinfo.nih.gov/ [Accessed 23 June 2004]. The latest US recommendations.
25. Royal College of Obstetricians and Gynaecologists. Management of HIV in Pregnancy. Guideline no. 39. London: RCOG Press; 2004. The latest British recommendations.
26. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Geneva: World Health Organization; 2004. The latest World Health Organization recommendations.
27. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-735.
28. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354:795-802.
29. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868. The 18-month follow-up of a pivotal single-dose nevirapine trial that shows that the benefits of treatment continue even in a breastfeeding population.
30. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292:202-209.
31. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362:1171-1177. The study shows that infant treatment with ARVs after birth reduces transmission even if the mother did not receive treatment.
32. Lallemant M, Jourdain G, Le Coeur S, et al. Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228. This study shows a further reduction in transmission rates by treating the mother-baby pair with two drugs.
33. Zijenah LS, Moulton LH, Iliff P, et al. ZVITAMBO Study Group. Timing of mother-to-child transmission of HIV-1 and infant mortality in the first 6 months of life in Harare, Zimbabwe. AIDS 2004; 18:273-280.
34. Stringer JS, Sinkala M, Goldenberg RL, et al. Universal nevirapine upon presentation in labour to prevent mother-to-child HIV transmission in high prevalence settings. AIDS 2004; 18:939-943.
35. Coutsoudis A, Pillay K, Kuhn L, et al. Methods of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15:379-387.
36. Kiarie JN, Richardson BA, Mbori-Ngacha D, et al. Infant feeding practices of women in a perinatal HIV-1 prevention study in Nairobi, Kenya. J Acquir Immune Defic Syndr 2004; 35:75-81.
37. Gottlieb D, Shetty AK, Mapfungautsi RM, et al. Infant feeding practices of HIV-infected and uninfected women in Zimbabwe. AIDS Patient Care STDS 2004; 18:45-53.